KCNA3 and type 1 diabetes mellitus: Since Kv1.3 blockers persistently inhibit the activation and proliferation of these T cells, Kv1.3 has emerged as an attractive pharmacological target in the treatment of several T-cell mediated autoimmune diseases such as Multiple Sclerosis, Type I diabetes, and asthma5, 6.